Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

Completed · Not applicable · Has a placebo group

Conditions studied: Binge Eating Disorder

In brief

This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.

Key facts

Study ID

NCT02317744

Run by

Yale University

People needed

22

Starts

2014-12-01

Expected to finish

2016-09-01

Last updated by the study team

2017-12-22

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)
• BMI between 30 kg/m2 and 50 kg/m2
• Not taking anti-depressant medications
• Read English proficiently enough to read study assessments
• Available for duration of treatment plus follow-up period
• Able to travel to study location (New Haven, CT) for monthly visits
• Agree to study procedures

You may not qualify if…

• Medical status judged by study physician as contraindication
• History of seizures
• Past or current anorexia nervosa, bulimia nervosa
• Current medications that influence eating/weight
• Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality) that requires immediate treatment
• Pregnant or breastfeeding

Where it is running

• Yale School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.